GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Elevation Oncology Inc (NAS:ELEV) » Definitions » ROE %

Elevation Oncology (Elevation Oncology) ROE % : -65.57% (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Elevation Oncology ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Elevation Oncology's annualized net income for the quarter that ended in Mar. 2024 was $-42.83 Mil. Elevation Oncology's average Total Stockholders Equity over the quarter that ended in Mar. 2024 was $65.31 Mil. Therefore, Elevation Oncology's annualized ROE % for the quarter that ended in Mar. 2024 was -65.57%.

The historical rank and industry rank for Elevation Oncology's ROE % or its related term are showing as below:

ELEV' s ROE % Range Over the Past 10 Years
Min: -100.23   Med: -88.03   Max: -54.48
Current: -65.81

During the past 5 years, Elevation Oncology's highest ROE % was -54.48%. The lowest was -100.23%. And the median was -88.03%.

ELEV's ROE % is ranked worse than
62.81% of 1358 companies
in the Biotechnology industry
Industry Median: -43.375 vs ELEV: -65.81

Elevation Oncology ROE % Historical Data

The historical data trend for Elevation Oncology's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Elevation Oncology ROE % Chart

Elevation Oncology Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
- - -54.48 -100.23 -88.03

Elevation Oncology Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -164.83 -76.34 -63.22 -53.91 -65.57

Competitive Comparison of Elevation Oncology's ROE %

For the Biotechnology subindustry, Elevation Oncology's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Elevation Oncology's ROE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Elevation Oncology's ROE % distribution charts can be found below:

* The bar in red indicates where Elevation Oncology's ROE % falls into.



Elevation Oncology ROE % Calculation

Elevation Oncology's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-45.704/( (49.032+54.809)/ 2 )
=-45.704/51.9205
=-88.03 %

Elevation Oncology's annualized ROE % for the quarter that ended in Mar. 2024 is calculated as

ROE %=Net Income (Q: Mar. 2024 )/( (Total Stockholders Equity (Q: Dec. 2023 )+Total Stockholders Equity (Q: Mar. 2024 ))/ count )
=-42.828/( (54.809+75.818)/ 2 )
=-42.828/65.3135
=-65.57 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2024) net income data. ROE % is displayed in the 30-year financial page.


Elevation Oncology  (NAS:ELEV) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-42.828/65.3135
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-42.828 / 0)*(0 / 99.026)*(99.026 / 65.3135)
=Net Margin %*Asset Turnover*Equity Multiplier
=N/A %*0*1.5162
=ROA %*Equity Multiplier
=N/A %*1.5162
=-65.57 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-42.828/65.3135
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-42.828 / -42.784) * (-42.784 / -39.476) * (-39.476 / 0) * (0 / 99.026) * (99.026 / 65.3135)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1.001 * 1.0838 * N/A % * 0 * 1.5162
=-65.57 %

Note: The net income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Elevation Oncology ROE % Related Terms

Thank you for viewing the detailed overview of Elevation Oncology's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Elevation Oncology (Elevation Oncology) Business Description

Traded in Other Exchanges
N/A
Address
888 Seventh Avenue, 12th Floor, New York, NY, USA, 10106
Elevation Oncology Inc is an oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Its lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have the potential to be therapeutically actionable through targeted HER3 inhibition.
Executives
Tammy Furlong officer: CHIEF FINANCIAL OFFICER C/O ELEVATION ONCOLOGY, INC., 888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106
Venbio Global Strategic Gp Iii, L.p. 10 percent owner 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Venbio Global Strategic Fund Iii, L.p. 10 percent owner 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Goodman Corey S 10 percent owner 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Robert J Adelman 10 percent owner 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Aaron Royston 10 percent owner 200 CARDINAL WAY, 2ND FLOOR, REDWOOD CITY CA 94063
David Dornan officer: Chief Scientific Officer C/O BOLT BIOTHERAPEUTICS, INC., 640 GALVESTON DRIVE, REDWOOD CITY CA 94063
Valerie Malyvanh Jansen officer: Chief Medical Officer C/O ELEVATION ONCOLOGY, INC., 888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106
Cormorant Asset Management, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Andrew N Schiff other: Managing Member PLANET ZANETT INC, 135 E 57TH ST, NEW YORK NY 10022
Steve Elms director, other: Managing Member 888 SEVENTH AVE, 29TH FL, NEW YORK NY 10106
Venbio Global Strategic Gp Iii, Ltd 10 percent owner 1700 OWENS STREET, SUITE 595, SAN FRANCISCI CA 94158
Qiming U.s. Healthcare Gp Ii, Llc 10 percent owner 11100 NE 8TH ST, SUITE 200, BELLEVUE WA 98004
Vertex Global Hc Fund Ii Pte. Ltd. 10 percent owner 250 NORTH BRIDGE ROAD, #11-01 RAFFLES CITY TOWER, SINGAPORE U0 179101
Walsh Colin director C/O ELEVATION ONCOLOGY, INC., 888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106